Life Science Investing Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson's Disease
Life Science Investing Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update
Life Science Investing Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease
Life Science Investing Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson's Patients at International Congress of Parkinson's Disease and Movement Disorders®
Life Science Investing Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson's Disease
Life Science Investing Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation
Life Science Investing Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update
LaFleur Minerals Closes LIFE, Flow Thru and Final Hard Dollar Offering for $900,000 to Complete Total of $7,800,421 Funding to Restart Beacon Gold Mill Production Operations in Abitibi Greenstone Belt
Nextech3D.ai Closes Krafty Labs Acquisition Expanding into a Comprehensive End-to-End AI-Powered Live Events and Experiential Engagement Platform
